Q2 2025 ADC Therapeutics SA Earnings Call Transcript
Key Points
- ADC Therapeutics SA (ADCT) reported net product revenues of $18.1 million for Q2 2025, slightly higher than the same period in the prior year.
- Promising data from the LOTIS-7 trial showed a 93.3% overall response rate and an 86.7% complete response rate in DLBCL patients.
- The company completed a $100 million private placement, extending its cash runway into 2028.
- ZYNLONTA plus glofitamab demonstrated a manageable safety profile with no new safety signals observed.
- ADC Therapeutics SA (ADCT) is on track to complete IND-enabling activities for its PSMA-targeting ADC by the end of the year, indicating progress in its pipeline.
- ADC Therapeutics SA (ADCT) incurred $13.1 million in restructuring and impairment costs in Q2 2025 due to strategic reprioritization and the closure of its U.K. facility.
- Total operating expenses increased by 8% over the prior year, driven by higher R&D costs.
- The company reported a net loss of $56.6 million for Q2 2025, compared to a net loss of $36.5 million in the same period in 2024.
- The strategic plan includes reducing the global workforce by approximately 30%, which may impact employee morale and operations.
- There is uncertainty regarding the maturity of overall survival data for the LOTIS-5 trial by the end of the year, which could affect regulatory discussions.
Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics SA ADCT Q2 2025 Earnings Conference Call. (Operator Instructions) This call is being recorded on Tuesday, August 12, 2025.
I will now turn the call over to Nicole Riley, Head of Investor Relations and Corporate Communications for ADC Therapeutics. Nicole, please go ahead.
Thank you, operator. Today, we issued a press release announcing our second quarter 2025 financial results and business updates. This release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website. I'm joined on today's call by our Chief Executive Officer, Ameet Mallik, who will discuss our operational performance and recent business highlights. Our Chief Medical Officer, Mohammad Zaki, who will discuss our clinical programs and updates; followed by our Chief Financial Officer, Pepe Carmona, who will review our second quarter 2025 financial results. We will then open the call to questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
